ÜBER DIESE EPISODE
Cancer immunotherapy research continues to evolve and offers patients a transformative alternative to traditional therapies. Anette Briendl, Senior Science Editor at BioWorld, talks about the current research landscape for immunotherapies. Learn about the challenges and potential of emerging therapies that are being developed, including the importance of checkpoint inhibitors and Car T-cells, to improve patient outcomes and how her work has provided incredible insight into developments in the immuno-oncology space.
Englisch
Großbritannien
TRANSKRIPT 🔗
Are you the producer of this podcast?
Add a podcast transcript
Need Audio-to-Text?
Transcribe with Listen411 in Just 60 Seconds
VERGANGENE FOLGEN SUCHEN
Vorhandene Folgen von Oncology Talks durchsuchen.
WEITERE EPISODEN IN DIESEM PODCAST
Recently, the U.S. Patent and Trademark Office’s released a dataset that contained over 250,000 records, included patent applications and granted patents; the USPTO was interested in the insights this data could reveal to guide cancer research. Di Cross, Director of Research at Clarivate Anal…
The recent buzz around CRISPR-Cas9, a genome editing tool, has revolved around its potential for treating various genetic diseases, including cancer. Jack Hopwood, Intellectual Property Consultant and Bertrand Sautier, Strategic Account Manager at Clarivate Analytics talk about how research activit…
Immuno-oncology therapies have opened up the most promising frontiers in cancer treatment today. But, with drug development costs increasing, how is it possible to maintain commercial viability?
Peter Winter, Editor at BioWorld, talks about challenges to commercial viability in the immuno-oncolog…
Join Chris Willis, Manager of Discovery and Translational Sciences at Clarivate Analytics, as he talks about immuno-oncology, why it is promising for cancer patients and how it continues to evolve. Learn more about the new approved drugs on the market that treat indications of cancer and the way in…
Rechtliche Hinweise: Der auf dieser Seite eingebettete Podcast und das Bildmaterial stammen von Clarivate Analytics – Formerly the IP&Science business of Thomson Reuters, das Eigentum seines Eigentümers ist und nicht mit Listen Notes, Inc. verbunden ist oder von diesen unterstützt wird.
BEARBEITEN
Vielen Dank, dass Sie uns helfen, die Podcast-Datenbank auf dem neuesten Stand zu halten.
